mosunetuzumab induces complete remissions in poor prognosis non-hodgkin lymphoma
Published 4 years ago • 487 plays • Length 9:36Download video MP4
Download video MP3
Similar videos
-
4:50
mosunetuzumab induces complete remissions in poor prognosis non-hodgkin lymphoma patients
-
4:13
stephen schuster: mosunetuzumab leads to durable complete remissions in non-hodgkin lymphoma
-
9:37
dual-targeted antibody mosunetuzumab elicits durable responses in poor-prognosis non-hodgkin lym...
-
4:46
mosunetuzumab induces deep and durable remissions in 3l r/r follicular lymphoma
-
5:25
pivotal findings from a phase i/ii trial of mosunetuzumab monotherapy for r/r follicular lymphoma
-
1:20
subcutaneous mosunetuzumab in r/r b-cell lymphoma
-
1:26
mosunetuzumab in b-nhl r/r to car-t
-
7:09
mosunetuzumab: next-generation antibody for follicular lymphoma
-
2:57
ash 2019 interview - dr laurie sehn - update: novel therapies in lymphoma
-
1:32
elizabeth budde, md, evaluates the clinical study investigating mosunetuzumab from ash 2018
-
7:16
dose-escalation of mosunetuzumab with polatuzumab vedotin for r/r b-cell non-hodgkin’s lymphoma
-
1:45
mosunetuzumab in b-nhl r/r to car-t
-
2:52
mosunetuzumab for chemotherapy-intolerant dlbcl
-
5:48
do early clinical data show synergy between mosunetuzumab and polatuzumab vedotin in r/r b-cell nhl?
-
4:13
how is lymphoma treated?
-
8:20
medicare patients receiving car t-cell therapy for non-hodgkin lymphoma: a first real-world look
-
1:21
bispecific mosunetuzumab shows promise in r/r follicular lymphoma and dlbcl
-
1:51
refract: standard chemoimmunotherapy versus novel agents in r/r follicular lymphoma
-
0:49
sunmo: mosunetuzumab polatuzumab vedotin vs r-gemox in r/r aggressive nhl